Document Detail

Anhedonia and ambivalence in schizophrenic patients with fronto-cerebellar metabolic abnormalities: a fluoro-d-glucose positron emission tomography study.
Jump to Full Text
MedLine Citation:
PMID:  20046378     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Prefrontal and cerebellar abnormalities have been associated with higher cognitive deficits in schizophrenia. The current study aimed to show whether or not schizophrenic patients with fronto-cerebellar functional abnormalities show more anhedonia or ambivalence.
METHODS: Regional cerebral metabolic activity was measured using fluoro-D-glucose positron emission tomography and was compared between 24 patients with chronic schizophrenia and 22 healthy normal volunteers. The existence of regional prefrontal hypofunction and regional cerebellar hyperfunction was investigated in each patient. Demographic and clinical variables including the emotional self-report scales were compared between the subgroups of the patients categorized according to the existence and the absence of the regional dysfunctions.
RESULTS: Comparisons between each patient and the total normal controls revealed that 14 of the total twenty-four patients had regional hypofrontal functions, whereas 11 patients had regional hypercerebellar functions. Patients with prefrontal hypofunction showed more severe anhedonia than those without prefrontal hypofunction, whereas patients with cerebellar hyperfunction compared to those without cerebellar hyperfunction had more severe ambivalence.
CONCLUSION: It seems that fronto-cerebellar abnormalities may be associated with cardinal emotional features of schizophrenia, such as anhedonia and ambivalence.
Authors:
Kyung-Min Park; Jae-Jin Kim; Jeong Ho Seok; Ji Won Chun; Hae-Jeong Park; Jong Doo Lee
Related Documents :
21876838 - Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic dif...
19224108 - Internal capsule size associated with outcome in first-episode schizophrenia.
11481168 - Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a rep...
10178498 - Economic outcomes associated with the use of risperidone in a naturalistic group practi...
1452178 - Knowing the patient: one aspect of clinical knowledge.
23392438 - Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstruct...
Publication Detail:
Type:  Journal Article     Date:  2009-06-30
Journal Detail:
Title:  Psychiatry investigation     Volume:  6     ISSN:  1976-3026     ISO Abbreviation:  Psychiatry Investig     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2010-01-04     Completed Date:  2011-07-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101242994     Medline TA:  Psychiatry Investig     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  72-7     Citation Subset:  -    
Affiliation:
Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Psychiatry Investig
Journal ID (publisher-id): PI
ISSN: 1738-3684
ISSN: 1976-3026
Publisher: Korean Neuropsychiatric Association
Article Information
Download PDF
Copyright © 2009 Official Journal of Korean Neuropsychiatric Association
open-access:
Received Day: 20 Month: 1 Year: 2009
Revision Received Day: 13 Month: 5 Year: 2009
Accepted Day: 19 Month: 5 Year: 2009
Print publication date: Month: 6 Year: 2009
Electronic publication date: Day: 30 Month: 6 Year: 2009
Volume: 6 Issue: 2
First Page: 72 Last Page: 77
ID: 2796050
PubMed Id: 20046378
DOI: 10.4306/pi.2009.6.2.72

Anhedonia and Ambivalence in Schizophrenic Patients with Fronto-Cerebellar Metabolic Abnormalities: A Fluoro-D-Glucose Positron Emission Tomography Study
Kyung-Min Park1
Jae-Jin Kim12
Jeong Ho Seok3
Ji Won Chun1
Hae-Jeong Park2
Jong Doo Lee2
1Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.
2Department of Nuclear Medicine, Yonsei Medical Center, Seoul, Korea.
3Department of Psychiatry, Hallym University Sacred Heart Hospital, Anyang, Korea.
Correspondence: Correspondence: Jae-Jin Kim, MD, PhD. Department of Psychiatry, Yonsei University College of Medicine, 712 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea. Tel +82-2-2019-3341, Fax +82-2-3462-4304, jaejkim@yonsei.ac.kr

Introduction

Schizophrenia is a debilitating disease with heterogeneous phenomenology and diverse symptoms.1 Among the variety of symptoms, both anhedonia and ambivalence are considered to be fundamental in patients with schizophrenia.2 Anhedonia is defined as a deficit in the ability to experience pleasant emotions, and ambivalence refers to a state of simultaneous and conflicting emotional valences toward a person or object.2 Therefore, the two symptoms could reflect some aspects of emotional disturbances that accompany schizophrenia.

However, patients with schizophrenia have a deficit in the ability to experience positive emotions related to future activities (anticipatory pleasure) but experience normal levels of positive emotions when directly engaged in pleasant activities (consummatory pleasure).3 This indicates that anhedonia may be caused by the disturbances in higher cognitive functioning, e.g. executive functions such as anticipation as well as emotional processing. In addition, ambivalence essentially induces approach-avoidance conflicts and thus higher cognitive functions are required to resolve conflicting emotional valences.4 Emotional disturbances in individuals with schizophrenia are thought to derive from abnormal interactions between the mesolimbic system and brain regions such as the prefrontal cortex and cerebellum that are responsible for higher cognitive functions.5,6 Therefore, the psychological and neural underpinnings of these two fundamental symptoms could be based on the interface between the neural substrates of emotion and higher cognition.

The prefrontal cortex and the cerebellum in the human are two brain regions that are massively larger by approximately one-third when compared to primates that lack capacities for higher cognitive functions.7 In addition, tract-tracing studies show that the cerebellum has strong connectivity between the prefrontal regions, which supports the notion that the cerebellum participates in neural circuits that perform higher cognitive functions of the prefrontal cortex.8 Therefore, the prefrontal cortex and the cerebellum are among a variety of brain regions considered to be key substrates for higher cognitive functions.6,9

Abnormalities in higher cognitive functions, hallmarks of schizophrenia, have been consistently connected to disrupted functioning of the prefrontal cortex and the cerebellum.9-12 Thus, the aim of this study was to examine whether patients with dysfunctional activity in these brain regions would show more severe anhedonia or ambivalence than subjects with normal activity at the same loci.

Abnormalities in higher cognitive functions in schizophrenia are associated with prefrontal hypofunction rather than hyperfunction, and cerebellar hypofunction10,13 or hyperfunction.9,14 The crucial roles of the cerebellum in the circuit responsible for higher cognitive functions are coordinating or modulating the activities in the prefrontal cortex, and therefore cerebellar activities could vary across features of required higher cognitive functions. Moreover, it is very difficult to connect a regional abnormality pattern to a specific clinical symptom in each individual patient, as most imaging results in schizophrenia have been obtained from analyzing the between-group differences or the within-group correlations. This is in part due to diverse functional patterns among individual patients with the illness as well as subtle variations in functional activities in the individuals.

Therefore, we investigated abnormal regional brain functions using 2-deoxy-2-18F-fluoro-glucose-positron emission tomography (18F-FDG-PET) in each individual patient when compared with total normal controls in order to predict those who would have abnormal functions in the prefrontal cortex and the cerebellum. We then compared the severities of anhedonia and ambivalence between patients with and without prefrontal hypofunction, and between patients with and without cerebellar hyperfunction. We hypothesized that the severities of anhedonia and ambivalence would be significantly different between the patient subgroups.


Methods
Subjects

The subjects were 24 patients with schizophrenia and 22 age-matched normal, healthy volunteers. The patients were recruited from the outpatient clinics at the Severance Mental Health Hospital (SMH), and had been in follow-up for more than two years. They fulfilled the DSM-IV criteria for schizophrenia, as diagnosed using the Structured Clinical Interview for DSM-IV (SCID).15 The exclusion criteria for the study were any lifetime history of neurological or other significant medical illnesses and any past history of substance abuse. The normal, healthy volunteers were recruited from the local community, and were screened for any current or lifetime history of a DSM-IV Axis I disorder using the SCID. The study was carried out under the guidelines established by the institutional review board of the SMH for research involving human subjects, and written informed consent was obtained from all subjects before the study began.

Each group contained the same number of men and women, and all participants were right-handed. The mean ages of the patient and normal control groups were 30.5 years (SD=3.5, range=23-36) and 30.3 years (SD=3.1, range=25-35), respectively. The mean years of education were 12.8 (SD=2.0) and 13.0 years (SD=1.6), respectively. Age and educational background were not significantly different between the groups. At the time of positron emission tomography (PET) scanning, the mean duration of illness in the patient group was 8.4 years (SD=3.8). All patients received either one or two neuroleptics, including risperidone, olanzapine, clozapine, aripiprazole and haloperidol, with a mean chlorpromazine- equivalent dose16 of 586.4 mg (SD=349.5).

Measurement of symptom severity and emotional characteristics

Symptom severity of the patients was assessed using the Positive and Negative Syndrome Scale17 within the week before PET scanning. The mean scores of schizophrenic symptom severities were calculated in the patient group: positive (mean=16.1, SD=3.2), negative (mean=17.0, SD=2.4), general (mean=34.0, SD=4.9), and total (mean=67.1, SD=8.9) symptoms.

Immediately after PET scanning, all subjects reported their own emotional tendencies by filling out four different self-report scales such as the physical and social anhedonia scales,18 the schizotypal ambivalence scale19 and the emotional expressivity scale.20 The physical anhedonia scale consists of 61 Yes-No questions and measures a deficit in the ability to experience pleasure, whereas the social anhedonia scale containing 40 items measures social withdrawal, a lack of interest and pleasure in social and interpersonal relationships. Scores of the physical anhedonia scale in the patients (mean=21.3, SD=9.6) were higher than those in the normal controls (mean=14.5, SD=6.9)(t=2.74, p<0.01), and scores of the social anhedonia scale in the patients (mean=15.5, SD=6.2) were also higher than those in the normal controls (mean=9.2, SD=5.1)(t=3.77, p<0.001). The schizotypal ambivalence scale consists of 19 Yes-No questions to identify ambivalence as characteristic of schizotypy and schizophrenia. Scores of the schizotypal ambivalence scale in the patients with schizophrenia (mean=10.6, SD=6.3) were higher than those in the normal controls (mean=6.2, SD=3.7)(t=2.95, p<0.01). The emotional expressivity scale, a 17-item 6-point scale, assesses the extent to which people outwardly display their emotions. Unlike other scales, scores of the emotional expressivity scale in the patients (mean=60.6, SD=8.6) were not significantly different from those in the normal controls (mean=65.6, SD=10.7). The demographic and scales data were analyzed using the Statistical Package for the Social Sciences (SPSS)(Version 13.0, Chicago, IL, USA) and the significance was set at p<0.05 (two-tailed).

Positron emission tomography procedures and imaging data preprocessing

PET images were acquired using a GE ADVANCE PET scanner (GE, Milwaukee, Wisconsin, USA) which had an intrinsic resolution of 4.8 mm full width at half maximum (FWHM) and a slice thickness of 4.25 mm for a longitudinal field of view of 15.2 cm. Subjects were asked to lie still with their eyes closed in a quiet, dimly lit room for 40 minutes after receiving an intravenous injection of approximately 185 MBq (5 mCi) of 18F-FDG. Afterwards, an 8-min transmission scan was performed using Ge-68 rod sources to correct for attenuation. The emission scan continued in 3-dimensional mode for 15 minutes. Gathered data were then reconstructed in a 128×128×35 matrix with a pixel size of 1.95×1.95×4.25 mm using a 3-dimensional filtered back-projection algorithm employing a transaxial 8.5 mm Hanning Filter and an 8.5 mm axial Ramp Filter.21

Spatial pre-processing and statistical analyses were performed using Statistical Parametric Mapping (SPM2, Institute of Neurology, University College of London, UK). All reconstructed images were spatially normalized into the MNI (Montreal Neurological Institute, McGill University, CA) standard PET template to remove the inter-subject anatomical variability. An affine transformation was performed to determine the 12 optimal parameters in order to register the brain on the template. Subtle differences between the transformed image and the template were removed by the nonlinear registration method using the weighted sum of the pre-defined smooth basis functions involved in discrete cosine transformation. Spatially normalized images were smoothed by convolution with an isotropic Gaussian kernel with 14 mm FWHM to increase the signal-to-noise ratio and accommodate for variations in subtle anatomical structures.

Statistical analysis

The effects of global metabolism were removed by normalizing the count of each voxel to the mean count of the brain (proportional scaling in SPM). In order to demonstrate abnormalities in each case, comparisons were made between each patient and the 22 total normal controls. Significant decreases and increases of the adjusted regional cerebral metabolism were obtained using t-statistics at every voxel. To facilitate interpretation, the t-values were transformed to Z-scores in the standard Gaussian distribution. The clusters consisting of a minimum of 50 contiguous voxels with the threshold of an uncorrected p<0.001 were considered to be significant. According to the a priori hypothesis that there would be prefrontal hypofunction and cerebellar hyperfunction in patients with schizophrenia, the existence or the absence of regional abnormal clusters in the prefrontal cortex and in the cerebellum were categorized into subgroups using the Talaraich coordinate system.22 Thereafter, demographic and clinical variables were compared between these defined subgroups using χ2-tests for categorical variables or independent t-tests for continuous variables. We used the Statistical Package for the Social Sciences (SPSS) (Version 13.0, Chicago, IL, USA), and significance of the differences was accepted when p<0.05 (two-tailed) in the analyses.


Results

As demonstrated in Table 1, comparisons between each patient and the total normal controls revealed that 14 of the total twenty-four patients had regional hypofrontal functions, and 11 patients had regional hypercerebellar functions. Six patients had both regional hypofrontal and hypercerebellar functions, 8 patients had only regional hypofrontal functions, and 5 patients had only regional hypercerebellar functions. However, 5 patients had no abnormalities in these brain regions.

Table 2 shows subgroup means of demographic and clinical variables according to whether or not the regional metabolic abnormalities were apparent. Most variables were unchanged whether or not abnormal functioning was evident. As shown in Figure 1, the only difference between the patient subgroups with and without regional hypofrontal function was observed in the physical anhedonia scale. On the other hand, the only difference between the patient subgroups with and without regional hypercerebellar function was identified in the schizotypal ambivalence scale.


Discussion

Our unique approach, in which each case and the total normal controls were compared, demonstrated that only 6 patients (25.0%) had both regional hypofrontal and hypercerebellar functions, whereas 5 patients (20.8%) had no abnormalities in these brain regions. It is well known that schizophrenia is a heterogeneous disorder. Previous studies have reported inconsistent brain activities in patients with schizophrenia during the resting state and even during the task-stimulating condition.23,24 As described in Table 1, regional activity patterns are variable among the patients, suggesting that results from the group comparison could be dependent on the composition of subjects. Therefore, the abnormalities in the two brain regions could not be generalized to problems of all patients with schizophrenia, but rather associated with some critical features rather than common problems in the patients with schizophrenia.

The patients with prefrontal hypofunction compared to those without prefrontal hypofunction showed more severe physical anhedonia, whereas the patients with cerebellar hyperfunction relative to those without cerebellar hyperfunction exhibited more severe ambivalence (Table 2, Figure 1). These results could suggest that the two symptoms have different neural correlates within the brain such as prefrontal-thalamic-cerebellar circuitry.25

In fact, patients with schizophrenia had a normal internal experience of positive emotion in the moment (consummatory pleasure), but they failed to anticipate or expect that future events would elicit these emotions (anticipatory pleasure).3 Behavioral studies indicated deficits in reward-related decision-making in patients with schizophrenia,26 and neuroimaging studies suggested that they failed to recruit reward-related brain regions while predicting future reward.27-30 Moreover, a recent study31 showed that they were impaired in amplification but not suppression of pleasant expressions. These results could suggest that hypofunction of the brain regions responsible for the anticipation of future pleasant activities is a critical neural substrate of anhedonia. It is well-established that the prefrontal cortex among various brain areas plays key roles in anticipation;32 in particular, the prefrontal cortex may be preferentially engaged in the positive emotions.33 Furthermore, the hypofrontality of schizophrenia is associated with impairments in executive functions such as anticipation.32 These findings our consistent with our results that patients with prefrontal hypofunction have more severe anhedonia than those without prefrontal hypofunction.

On the other hand, core roles of the cerebellum in the higher cognitive functions include rapid, online error detection, modulation, and coordination, culminating in the production of mental representations in a fine-tuned pattern. The cerebellum is activated in a variety of mental activities including facial recognition, emotional attribution, theory of mind, directed attention and many types of memory.6 In order to resolve ambivalence by simultaneously representing conflicting emotional valences,4 individuals may have to detect the errors driven from the conflicting emotional representations, modulate and coordinate the representations and the errors in a rapid and online manner, and then produce the integrated mental representations in a fine-tuned pattern. Therefore, it may be possible that hyperfunction of the cerebellum may reflect enhanced difficulty in resolution of ambivalence. This possibility could be supported by our finding indicating that the patients with cerebellar hyperfunction have more severe ambivalence than those without cerebellar hyperfunction.

A limitation of our study was that the patients with schizophrenia were all medicated with antipsychotics. There are reports that antipsychotic medications affect cerebellar and even prefrontal functions.34,35 However, it has to be emphasized that both prefrontal hypofunction and cerebellar hyperfunction were found in drug-naїve first-episode patients with schizophrenia.14 Another caveat is that we used self-report scales to measure the emotional tendencies. Because of the problem of low reliability in the scales, it is possible that the exact emotional states of the subjects were not reflected. Another limitation is that our major findings were obtained from the comparisons between patient subgroups, and there were only a small number of subjects in each patient subgroup. In addition, the validity of our approach, in which each case and the total normal controls were compared, might need to be confirmed by future investigations, though it was used only to set up the patient subgroups.

In conclusion, this study found that the patients with prefrontal hypofunction tended to have more severe anhedonia than those without prefrontal hypofunction, whereas the patients with cerebellar hyperfunction tended to show more severe ambivalence than those without cerebellar hyperfunction. Therefore, these results support the notion that prefronto-cerebellar abnormalities are associated with cardinal features of schizophrenia, such as anhedonia and ambivalence.


Acknowledgments

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2008 (6-2008-0238).


References
1. Andreasen NC,Carpenter WT Jr. Diagnosis and classification of schizophreniaSchizophr BullYear: 1993191992148322032
2. Mann MC,Vaughn AG,Barrantes-Vidal N,Raulin ML,Kwapil TR. The schizotypal ambivalence scale as a marker of schizotypyJ Nerv Ment DisYear: 200819639940418477882
3. Gard DE,Kring AM,Gard MG,Horan WP,Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasureSchizophr ResYear: 20079325326017490858
4. van Harreveld F,van der Pligt J,de Liver YN. The agony of ambivalence and ways to resolve it: introducing the MAID modelPers Soc Psychol RevYear: 200913456119144904
5. Crespo-Facorro B,Paradiso S,Andreasen NC,O'Leary DS,Watkins GL,Ponto LL,et al. Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odorsJAMAYear: 200128642743511466121
6. Andreasen NC,Pierson R. The role of the cerebellum in schizophreniaBiol PsychiatryYear: 200864818818395701
7. Middleton FA,Strick PL. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive functionScienceYear: 19942664584617939688
8. Middleton FA,Strick PL. Cerebellar projections to the prefrontal cortex of the primateJ NeurosciYear: 20012170071211160449
9. Kim JJ,Mohamed S,Andreasen NC,O'Leary DS,Watkins GL,Boles Ponto LL,et al. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomographyAm J PsychiatryYear: 200015754254810739412
10. Allen G,Buxton RB,Wong EC,Courchesne E. Attentional activational of the cerebellum independent of motor involvementScienceYear: 1997275194019439072973
11. Raichle ME,Fiez JA,Videen TO,MacLeod AM,Pardo JV,Fox PT,et al. Practice-related changes in human brain functional anatomy during nonmotor learningCereb CortexYear: 199448268180494
12. Kim JJ,Andreasen NC,O'Leary DS,Wiser AK,Ponto LL,Watkins GL,et al. Direct comparison of the neural substrates of recognition memory for words and facesBrainYear: 1999122Pt 61069108310356060
13. Crespo-Facorro B,Nopoulos PC,Chemerinski E,Kim JJ,Andreasen NC,Magnotta V. Temporal pole morphology and psychopathology in males with schizophreniaPsychiatry ResYear: 200413210711515598545
14. Andreasen NC,O'Leary DS,Flaum M,Nopoulos P,Watkins GL,Boles Ponto LL,et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patientsLancetYear: 1997349173017349193383
15. First MB,Spitzer RL,Gibbon M,Williams JBW. Structured Clinical Interview for DSM-IV Axis I DisordersYear: 1996New YorkNew York State Psychiatric Institute Biometrics Research
16. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychoticsJ Clin PsychiatryYear: 20036466366712823080
17. Kay SR,Fiszbein A,Opler LA. The positive and negative syndrome scale (PANSS) for schizophreniaSchizophr BullYear: 1987132612763616518
18. Chapman LJ,Chapman JP,Raulin ML. Scales for physical and social anhedoniaJ Abnorm PsycholYear: 197685374382956504
19. Raulin ML,Brenner V. Costello CGAmbivalenceSymptoms of schizophreniaYear: 1993New YorkWiley201226
20. Kring AM,Smith DA,Neale JM. Individual differences in dispositional expressiveness: development and validation of the Emotional Expressivity ScaleJ Pers Soc PsycholYear: 1994669349498014836
21. Kinaha PE,Rogers JG. Analytic 3D image reconstruction using all detected eventsIEEE T Nucl SciYear: 198936964968
22. Talairach J,Tournoux P. Co-planar stereotaxic atlas of the human brainYear: 1988New YorkThieme
23. Weinberger DR,Berman KF,Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidenceArch Gen PsychiatryYear: 1986431141243947207
24. Toone BK,Okocha CI,Sivakumar K,Syed GM. Changes in regional cerebral blood flow due to cognitive activation among patients with schizophreniaBr J PsychiatryYear: 200017722222811040882
25. Andreasen NC,O'Leary DS,Cizadlo T,Arndt S,Rezai K,Ponto LL,et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitryProc Natl Acad Sci U S AYear: 199693998599908790444
26. Heerey EA,Robinson BM,McMahon RP,Gold JM. Delay discounting in schizophreniaCogn NeuropsychiatryYear: 20071221322117453902
27. Juckel G,Schlagenhauf F,Koslowski M,Wüstenberg T,Villringer A,Knutson B,et al. Dysfunction of ventral striatal reward prediction in schizophreniaNeuroimageYear: 20062940941616139525
28. Juckel G,Schlagenhauf F,Koslowski M,Filonov D,Wüstenberg T,Villringer A,et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neurolepticsPsychopharmacology (Berl)Year: 200618722222816721614
29. Murray GK,Corlett PR,Clark L,Pessiglione M,Blackwell AD,Honey G,et al. How dopamine dysregulation leads to psychotic symptoms? Abnormal mesolimbic and mesostriatal prediction error signalling in psychosisMol PsychiatryYear: 20081323917684497
30. Murray GK,Corlett PR,Clark L,Pessiglione M,Blackwell AD,Honey G,et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosisMol PsychiatryYear: 20081323926727617684497
31. Henry JD,Green MJ,de Lucia A,Restuccia C,McDonald S,O'Donnell M. Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional bluntingSchizophr ResYear: 20079519720417630254
32. Berman KF,Torrey EF,Daniel DG,Weinberger DR. Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophreniaArch Gen PsychiatryYear: 1992499279341360197
33. Warren JE,Sauter DA,Eisner F,Wiland J,Dresner MA,Wise RJ,et al. Positive emotions preferentially engage an auditory-motor "mirror" systemJ NeurosciYear: 200626130671307517167096
34. Holcomb HH,Cascella NG,Thaker GK,Medoff DR,Dannals RF,Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidolAm J PsychiatryYear: 199615341498540590
35. Loeber RT,Gruber SA,Cohen BM,Renshaw PF,Sherwood AR,Yurgelun-Todd DA. Cerebellar blood volume in bipolar patients correlates with medicationBiol PsychiatryYear: 20025137037611904131

Article Categories:
  • Original Article

Keywords: Schizophrenia, Fronto-cerebellar abnormalities, Fluoro-D-glucose positron emission tomography, Anhedonia, Ambivalence.

Previous Document:  Accept or refuse? A pilot study of patients' perspective on participating as imaginary research subj...
Next Document:  Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment.